Investment bank raises guidance for Novo Nordisk after "impressive" Wegovy launch
An "impressive" launch of Novo Nordisk's new obesity treatment Wegovy has led US investment group Jefferies to increase its expectations for the Danish pharmaceutical company.
BY MARKETWIRE, TRANSLATED BY CATHERINE BRETT
Novo Nordisk's share price target has been increased from USD 66 (DKK 415) to USD 74 (DKK 465) by US investment bank Jeffries after an "impressive" launch, the bank reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
